A Phase 1/Randomized Phase 2 Study to Evaluate LY2603618 in Combination With Pemetrexed and Cisplatin in Patients With Stage IV Non-small Cell Lung Cancer.
Phase of Trial: Phase I/II
Latest Information Update: 01 Jun 2017
At a glance
- Drugs Rabusertib (Primary) ; Cisplatin; Pemetrexed
- Indications Mesothelioma; Non-small cell lung cancer; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors Eli Lilly
- 14 Sep 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 21 Apr 2014 Planned End Date changed from 1 Mar 2014 to 1 Mar 2015 as reported by ClinicalTrials.gov.
- 30 Oct 2013 Planned end date changed from 1 Nov 2013 to 1 Mar 2014 as reported by ClinicalTrials.gov.